Results 61 to 70 of about 27,419 (207)

Facilitating Expedited Drug Approval—the Past, Present, and Future of Clinical Trials for Pediatric Rheumatic Disease

Arthritis Care &Research, EarlyView.
Pamela F. Weiss, Hermine I. Brunner
wiley   +1 more source

Clinical Features of Regorafenib‐induced Liver Injury in Japanese Patients From Postmarketing Experience

Clinical colorectal cancer, 2017
Background: Regorafenib (Stivarga) is an oral multikinase inhibitor currently approved for patients with metastatic colorectal cancer or gastrointestinal stromal tumor. Although hepatotoxicity has been a known product profile feature of regorafenib since
H. Uetake, K. Sugihara, K. Muro, T. Sunaya, Yuka Horiuchi‐Yamamoto, H. Takikawa   +5 more
semanticscholar   +1 more source

Progress in Natural Products Target Discovery Technology

MedComm, Volume 7, Issue 6, June 2026.
Here, we provide a comprehensive overview of current technologies and recent advancements in therapeutic target discovery for natural products. By systematically synthesizing the principles, methodologies, and practical applications of existing experimental and computational strategies, this work provides a more actionable reference framework for ...
Qiyuan Pan, Xiao Yuan, Jinmei Jin, Xin Luan, Cheng Luo, Hongzhuan Chen, Weidong Zhang, Hao Zhang   +7 more
wiley   +1 more source

Reações adversas a medicamentos em pediatria: uma revisão sistemática de estudos prospectivos Adverse drug reactions in pediatrics: a systematic review of prospective studies

Revista Brasileira de Saúde Materno Infantil, 2004
O objetivo desta revisão foi explorar e comparar as informações derivadas de estudos prospectivos sobre a incidência de reações adversas a medicamentos (RAM) em pediatria, publicados de janeiro de 1966 a novembro de 2003 em revistas indexadas nas bases ...
Djanilson Barbosa dos Santos, Helena Lutéscia Luna Coelho   +1 more
doaj   +1 more source

Indian clinical experience on an innovative product in the management of polycystic ovary syndrome

, 2020
Even today, polycystic ovary syndrome (PCOS) and its management remains a challenge. The entry of innovative products in the clinical armamentarium for PCOS management is welcome and needs to be investigated for their efficacy and safety in Indian women ...
Bharati Gawade, R. Hegde
semanticscholar   +1 more source

Characteristics of safety information obtained from postmarketing observational studies for re-examination in Japan

SpringerPlus, 2016
BackgroundIn Japan, postmarketing surveillance (PMS) studies are required for newly approved drug products to further collect safety information in clinical settings.
Tatsuya Watanabe, M. Narukawa
semanticscholar   +1 more source

Age‐Dependent Differences in Canakinumab Safety: A Comprehensive Pharmacovigilance Analysis Using the FAERS Database

Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT While the efficacy of canakinumab, an anti‐interleukin‐1β monoclonal antibody, is well‐established, its safety profile, particularly across different age groups, remains inadequately explored. Using the FDA Adverse Event Reporting System (FAERS) database, this study evaluated postmarketing safety by analyzing adverse event (AE) reports from ...
Youyang Wang, Ngasin Lam, Xiaoming Huang, Yang Jiao   +3 more
wiley   +1 more source

Recent Advances and Future Directions in Bellafill as a Regenerative Biomaterial: Biological Mechanisms, Clinical Applications, and Safety

Journal of Cosmetic Dermatology, Volume 25, Issue 6, June 2026.
ABSTRACT Background Bellafill is a polymethylmethacrylate (PMMA) microsphere‐collagen composite increasingly recognized as a scaffold‐based injectable biomaterial rather than a temporary filler. Its non‐resorbable PMMA microspheres enable stable integration into host tissue and promote collagen neogenesis, fibroblast activation, and extracellular ...
Li Nan, Fang Xia, Ahmad Alhaskawi, Chenggang Yi, Pengchao Guo   +4 more
wiley   +1 more source

In vivo recovery and safety of human factor VIII product AAFACT in patients with haemophilia A

, 2003
AAFACT, a monoclonal purified, solvent/detergent treated human plasma-derived coagulation factor VIII concentrate obtained from plasma of voluntary, non-remunerated blood donors, is manufactured and marketed in the Netherlands by Sanquin Plasma Products ...
Koopman, MMW, van den Berg, H.M., Vossebeld, P. J. M., de Goede-Bolder, A., Leebeek, F. W. G., Leebeek, Frank, Faber, A., Novakova, I. R. O., van den Berg, HM, Grob, P, Peters, M, Berg, H.M. van den, Gerrits, WBJ, Novakova, IRO, Goede-Bolder, A. de, Gerrits, W.B.J., Koopman, M. M. W., Koopman, M.M.W., van den Berg, H. M., Vossebeld, PJM, Tissing, M. H., Bolder, A, Grob, P., Tissing, M.H., Tissing, MH, Strengers, P. F. W., Vossebeld, P.J., Vossebeld, P.J.M., Gerrits, W. B. J., Koopman, M., Nováková, I.R.O., Faber, A, Leebeek, F.W., Strengers, P.F.W., Hiemstra, H, Leebeek, Frank; id_orcid, Hiemstra, H., Peters, M., Strengers, PFW   +38 more
core   +1 more source

Adverse Drug Reaction Study of Botulinum Toxin‐A in the Real World

Journal of Cosmetic Dermatology, Volume 25, Issue 6, June 2026.
ABSTRACT Background Despite the increasing use of botulinum toxin type A (BoNT‐A) in aesthetic and therapeutic applications, its real‐world adverse drug reaction (ADR) profile remains incompletely characterized. Current evidence relies largely on small‐scale clinical observations rather than large, systematic analyses.
Jiaxu Gu, Yue Sun, Kexin Chen, Jieyi Wang, Bingcheng Lu, Hongqiang Xie, Xiaoming Liu, Cong Huang, Xingling Jian, Bo Yu   +9 more
wiley   +1 more source